Press releases

CellCentric launches clinical programme in blood cancers led by Prof Andy Davies

12 Feb 2019

CellCentric is initiating a clinical study of CCS1477, a first-in-class p300/CBP inhibitor, in haematological malignancies. CCS1477 is already in Phase I studies for late stage prostate cancer. The clinical programme is being extended to include acute myeloid leukaemia (AML), multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) following new pre-clinical data showing profound anti-tumour effects of CCS1477 in models of these haematological malignancies. The Chief Investigator for the new Phase I/II clinical study will be Prof Andy Davies of University Hospital Southampton. The trial is expected to open for recruitment in Q2 2019.

CCS1477 is a novel, highly potent and specific inhibitor of the common bromodomain of two critical cancer regulatory proteins, p300 and CBP. The drug is formulated as a capsule to be taken orally. Inhibiting p300/CBP in blood cancers affects the IRF4-Myc pathway and can have a significant impact on tumour growth in pre-clinical models. CellCentric is now transitioning the product into haematological cancer clinical trials.

Andy Davies is Professor of Haematological Oncology and Consultant in Medical Oncology within The Faculty of Medicine at the University of Southampton. He has specific interests in the clinical course of malignant lymphoma, the investigation of novel therapeutic approaches and biomarker identification. He has extensive experience in early phase trials, including leading several first in man lymphoma studies. He is Chair of the UK National Cancer Research Institute High Grade Lymphoma Study Group and Director of Cancer Research UK/National Institute of Health Southampton Experimental Cancer Medicine Centre.

CCS1477 is currently enrolling patients in a Phase I/II clinical trial for late stage prostate cancer, with Prof Johann de Bono of the Royal Marsden Hospital, as the Chief Investigator. The drug is positioned to be used after or in combination with second generation anti-hormonal drugs such as abiraterone, enzalutamide and apalutamide. The mode of action of CCS1477 addresses the primary resistance mechanisms to these current agents, whether inherent or acquired.

Dr Nigel Brooks, CellCentric’s Director of Translational Research, commented: “At CellCentric and with our network of scientific collaborators, we have generated new and compelling pre-clinical data showing profound anti-tumour effects of CCS1477 in models of AML, MM and NHL. We are excited to now translate these findings into the clinic. We look forward to working with Prof Andy Davies and other clinical experts as we develop this novel approach for the benefit of patients with haematological cancers.”

The clinical need and potential market for a new agent for late blood cancers remains significant. Particularly in late stage relapsed refractory multiple myeloma the market could be in the tens of thousands of patients to treat each year.

CellCentric will be presenting CCS1477 in the ‘New Drugs on the Horizon’ session at AACR in Atlanta, on the 31st March 2019.

About CellCentric

CellCentric is a biotechnology company focused on a first-in-class p300/CBP bromodomain inhibitor drug, CCS1477. The company has investigated over 50 potential epigenetic-related drug targets, before focusing on the twin histone acetyl transferases p300/CBP. An earlier programme, based on an arginine methyltransferase target, was licenced to Takeda Pharmaceuticals. CCS1477 has relevance to multiple cancer types, and notably for late-stage, castration-resistant prostate cancer (CRPC) as well as haematological cancers (AML, multiple myeloma, lymphoma).

CellCentric is a privately held business, with Morningside Venture Investments as its lead investor. CCS1477’s progress has also benefited from awards from Innovate UK (BioMedical Catalyst) and the Prostate Cancer Foundation. The company maintains active collaborations with multiple research centres in Europe and the US.